We are inviting applications for early-career researchers (ECRs) to join our research grant evaluation committee as part of our annual internship scheme.

Although a clinical setback last year continues to loom in the background, AbbVie’s $8.7 billion bet on Cerevel Therapeutics has paid off with its first approval from the FDA.  | Although a clinical s...

This pilot trial evaluated the one-year tolerability of oral N-acetylcysteine (NAC) 1200 mg/day in Parkinson’s disease (PD) and explored associations with clinical progression, levodopa dose, and stri...

Athens-based biotech will use the financing to advance AT001, its lead therapeutic program targeting the LRRK2–FADD interaction, through a key in vivo efficacy study.

Subscription and open access journals from Sage, the world's leading independent academic publisher.

Background α-Synuclein aggregation is a pathological hallmark of synucleinopathies, including Parkinson's disease (PD) and multiple system atrophy (MSA). Although pathogenic α-synuclein seeds can be.....

Introduction Limited real-world data exist around the long-term impact of uncontrolled motor fluctuations in Parkinson’s disease (PD). With this first-ever, prospective, observational study, we sought...

Explore the pros and cons of Adaptive Deep Brain Stimulation, highlighting patient control issues and potential for better real-world data integration.

Recent advances in Parkinson's disease (PD) therapeutics have generated new opportunities for both symptomatic and disease-modifying treatments. This review discusses four therapeutic approaches that ...

Background Preclinical studies have suggested that DL-3-n-butylphthalide (NBP) may exhibit neuroprotective effects in neurodegenerative diseases; however, no human trial has evaluated NBP in spinoce...

Ruppert-Junck et al. review how compensation and reserve—two components of resilience—help the brain to mitigate the effects of dopaminergic loss in Parkin